Functional study of pancreatic cancer has shown that stimulation of ER stress under the mutant KRAS expressing condition, which has higher sensitivity to stimulants for ER stress, such as tunicamycin, brefeldin A, and bortezomib, results in an anticancer effect in mutant KRAS expressing conditions [44]. This evidence concerns the gene KRAS and familial pancreatic carcinoma.